Ontology highlight
ABSTRACT:
SUBMITTER: Torka P
PROVIDER: S-EPMC6988401 | biostudies-literature | 2020 Jan
REPOSITORIES: biostudies-literature
Torka Pallawi P Kothari Shalin K SK Sundaram Suchitra S Li Shaoying S Medeiros L Jeffrey LJ Ayers Emily C EC Landsburg Daniel J DJ Bond David A DA Maddocks Kami J KJ Giri Anshu A Hess Brian B Pham Luu Q LQ Advani Ranjana R Liu Yang Y Barta Stefan Klaus SK Vose Julie M JM Churnetski Michael C MC Cohen Jonathon B JB Burkart Madelyn M Karmali Reem R Zurko Joanna J Mehta Amitkumar A Olszewski Adam J AJ Lee Sarah S Hill Brian T BT Burns Timothy F TF Lansigan Frederick F Rabinovich Emma E Peace David D Groman Adrienne A Attwood Kristopher K Hernandez-Ilizaliturri Francisco J FJ
Blood advances 20200101 2
There is a paucity of data regarding outcomes and response to standard therapy in patients with limited-stage (LS) agressive B-cell lymphoma (LS-ABCL) who harbor MYC rearrangement (MYC-R) with or without BCL2 and/or BCL6 rearrangements. We conducted a multicenter retrospective study of MYC-R LS-ABCL patients who received either rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), or more intensive immunochemotherapy (IIC) plus or minus consolidative involved-field radi ...[more]